48th week of 2013 patent applcation highlights part 50 |
Patent application number | Title | Published |
20130317058 | OPHTHALMIC COMPOSITION FOR ENABLING DILATION OF PUPILS - The present invention discloses an ophthalmic composition for ophthalmic application(s) inclusive of Eye examination, surgeries carried out in the posterior chamber of the Eye like cataract surgery. The said composition comprises at least three active ingredients. The said ingredients may be inclusive of, but not restricted to, Epinephrine Bitartrate, Atropine Bisulphate, Xylocaine Hydrochloride and additives like, antioxidant compounds, buffers and the like. The said composition comes in a packaging container inclusive of sterile package such as vial/ampoule/prefilled syringes. The said composition can be directly injected in the Eye in order to bring about effective and speedy dilation of the pupil(s), in particular pupil(s) of relatively smaller dimension than normal pupil. The three active ingredients are mixed in a predefined percentage range in a predefined volume and the composition is supplied in a sterile package. | 2013-11-28 |
20130317059 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES - A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof. | 2013-11-28 |
20130317060 | Solid Forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide - The present invention relates to solid state forms of N—[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith. | 2013-11-28 |
20130317061 | Crystalline Salts of a Potent HCV Inhibitor - This invention relates to novel tris(hydroxymethyl)aminomethane, choline and N-methyl-D-glucamine salt forms of the following Compound (1) and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection: | 2013-11-28 |
20130317062 | INSECTICIDAL PHENYL-OR PYRIDYL-PIPERDINE COMPOUNDS - A compound of formula (I) | 2013-11-28 |
20130317063 | ORAL CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF BEPOTASTINE - The present invention relates to oral controlled release pharmaceutical compositions comprising Bepotastine. The oral controlled release pharmaceutical composition comprises Bepotastine or pharmaceutically acceptable salts thereof and at least one release controlling agent. The present invention also provides the use of oral controlled release pharmaceutical compositions of Bepotastine for the treatment of allergic rhinitis and for the treatment of pruritus caused by urticaria. | 2013-11-28 |
20130317064 | MICROBIOCIDAL PYRAZOLE DERIVATIVES - The present invention provides compounds of formula I: wherein the substituents are as defined in claim | 2013-11-28 |
20130317065 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF - The present invention provides a compound represented by the general formula (I) of the present invention, which has EP | 2013-11-28 |
20130317066 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES - Compounds useful in the treatment of mammalian cancers and especially human cancers according to Formula I are disclosed. | 2013-11-28 |
20130317067 | PESTICIDAL MIXTURES WITH IMPROVED PROPERTIES - The present invention relates to novel pesticidal compositions comprising the crystalline modification I of 4-{[(6-chloropyrid-3-yl)methyl](methyl)amino}furan-2(5H)-one and a fungicidally active compound that show surprisingly good insecticidal, acaricidal, nematicidal and fungicidal activities. In particular, these compositions are suited for the treatment of seed. | 2013-11-28 |
20130317068 | SUBSTITUTED 1,2,4-TRIAZOLE COMPOUNDS AS A SEED TREATMENT TO CONTROL PESTS - Methods of using substituted 1,2,4-triazole compounds as a seed treatment to control pests, such as insects and mites. | 2013-11-28 |
20130317069 | 2,4-(SUBSTITUTED AROMATIC)-1,3-OXAZOLINE COMPOUNDS AS A SEED TREATMENT TO CONTROL PESTS - Methods of using 2,4-(substituted aromatic)-1,3-oxazoline compounds as a seed treatment to control pests, such as insects and mites. | 2013-11-28 |
20130317070 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS - The invention provides for the use of antimicrobial chemical entities based on a nitrothiazolide backbone that exhibit anti-mycobacteria activity, including the mycobacterium causing tuberculosis. Multiple compounds were synthesized and screened for anti-tuberculosis activity. Disclosed herein are a series of compounds with anti-tuberculosis activity, including six leads that completely inhibited bacterial growth at 5 micrograms per ml or less. Three of these compounds were tested to determine MIC and these ranged between 1 and 4 micrograms per ml against both drug susceptible | 2013-11-28 |
20130317071 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS - Novel compounds of formula 1 | 2013-11-28 |
20130317072 | Method To Enhance Delivery Of Glutathione And ATP Levels In Cells - A therapeutic method is provided comprising treating a mammal subject to hypoxia with an amount of 2(R,S)-D-ribo-(1′,2′,3′,4′-tetrahydroxybutyl)thiazolidine-4(R)-carboxylic acid (RibCys) or a pharmaceutically acceptable salt thereof effective to both maintain, restore or increase both the ATP levels and the glutathione (GSH) levels in said tissue. | 2013-11-28 |
20130317073 | METHODS OF PEST CONTROL IN SOYBEAN - The present invention provides methods comprising applying to a crop of soybean plants, the locus thereof, or propagation material thereof, a compound a compound of formula III wherein A | 2013-11-28 |
20130317074 | TOPICAL ANTIFUNGAL AGENT - An anti-fungal agent for tinea comprising as active ingredient a compound having the skeleton of 2-(1H-pyrazol-1-yl)phenol represented by the following formula (I) or (II) or a salt thereof is provided | 2013-11-28 |
20130317075 | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexa- ne-1,1'-pyrano[3,4,b]indol]-4-amine and a NSAR - The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is a non-steroidal anti-rheumatic drug selected from the group consisting of indometacin, diclofenac, sulindac, tolmetin, zomepirac, aclofenac, bumadizone, etodolac, lonazolac, fentiazac, acemetacin, difenpiramide, oxametacin, proglumetacin, ketorolac, aceclofenac, bufexamac, mefenamic acid, tolfenamic acid, flufenamic acid, meclofenamic acid, and the physiologically acceptable salts thereof. | 2013-11-28 |
20130317076 | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexa- ne-1,1'-pyrano-[3,4,b]indol]-4-amine and a Salicylic Acid Component - The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is a salicylic acid component selected from the group consisting of acetylsalicylic acid, salicylic acid, salicylamide, ethenzamide, salsalate, dipyrocetyl, benorilate, diflunisal, guacetisal, and the physiologically acceptable salts thereof. | 2013-11-28 |
20130317077 | COMPOSITION FOR PREVENTING OR TREATING OBESITY, DYSLIPIDEMIA, FATTY LIVER OR DIABETES CONTAINING INDOLE-3-CARBINOL DERIVATIVE AS ACTIVE INGREDIENT - Disclosed is a composition for preventing or treating obesity, dyslipidemia, fatty liver or diabetes, containing an indole-3-carbinol derivative as an active ingredient. The indole-3-carbinol derivative of the present disclosure can be usefully used as a pharmaceutical or functional food composition for preventing or treating obesity, dyslipidemia, fatty liver or diabetes by inhibiting differentiation of preadipocytes and reducing accumulation of triglyceride in cells. | 2013-11-28 |
20130317078 | PHENYLALKYL N-HYDROXYUREAS FOR TREATING LEUKOTRIENE RELATED PATHOLOGIES - The method of treating patients by administering N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea for treatment of leukotriene related pathologies, and compositions for this use. | 2013-11-28 |
20130317079 | Poly(acrylate) Polymers for In Vivo Nucleic Acid Delivery - The present invention is directed membrane active poly(acrylate) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides cells in vivo. RNAi polynucleotides are conjugated to the poly(acrylate) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(acrylate) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness. | 2013-11-28 |
20130317080 | MODIFIED iRNA AGENTS - The present invention provides effective motifs for RNA agents conjugated to at least one ligand, which are advantageous for the in vivo delivery of iRNA duplex agents. Additionally, the present invention provides methods of making these compositions, as well as methods of introducing these iRNA duplex agents into cells using these compositions, e.g., for the treatment of various disease conditions. | 2013-11-28 |
20130317081 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF - The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia. | 2013-11-28 |
20130317082 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER - Methods and compositions are provided for the diagnosis and treatment of gastric cancers associated with amplification or overexpression of the c-Myb gene. | 2013-11-28 |
20130317083 | NON-CODING TRANSCRIPTS FOR DETERMINATION OF CELLULAR STATES - Disclosed herein are novel methods, assays and systems for determining a given state of a cell or a tissue by detecting the presence or absence of a short RNA molecule originating from (a) at least one or more exons of at least one or more protein-coding genes, or from (b) at least one or more segments of at least one or more non-coding transcripts, or from (c) both (a) and (b), in a biological sample from a subject. In some embodiments, the methods, assays and systems described herein can be used to identify an origin and/or a type of a cell or tissue, and/or distinguish a cell or tissue from another cell or tissue. In some embodiments, the methods, assays and systems described herein can also be used to diagnose a disease or disorder, or prognose a given stage and/or progression of the disease or disorder in a subject. | 2013-11-28 |
20130317084 | METHOD OF TREATING DIABETES - The present invention relates to a method for treating a subject having or at risk of a diabetes-related disorder. In a preferred embodiment, the method involves increasing the level or activity of Hypoxia Induced Factor 1 (HIF-1α) in pancreatic-β-cells or insulin-sensitive tissues in the subject by administering to the subject an inhibitor of a protein that decreases the level or activity of HIF-1α. The present invention also relates to a method of transplanting pancreatic islet cells in a subject. | 2013-11-28 |
20130317085 | MODULATION OF APOLIPOPROTEIN C-III EXPRESSION - Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III. Methods of using these compounds for modulation of apolipoprotein C-III expression and for diagnosis and treatment of disease associated with expression of apolipoprotein C-III are provided | 2013-11-28 |
20130317086 | NEURAL TRANSFECTION REAGENTS - The invention is directed to transfection reagents for the delivery of nucleic acids into neural cells, compositions including the reagents, methods of preparation of such reagents, methods of transfecting cells with such reagents, and uses thereof. In preferred embodiments the reagents comprise horseradish peroxidase and/or a polycarboxylic acid such as poly(acrylic acid) or poly(methacrylic acid). | 2013-11-28 |
20130317087 | METHODS AND COMPOSITIONS RELATED TO STAUFEN 1 BINDING SITES FORMED BY DUPLEXING ALU ELEMENTS - Disclosed are compositions and methods for identifying binding sites of targets of Staul-mediated mRNA decay; methods and compositions for treating subjects with conditions resulting from Staul-mediated mRNA decay, and method of screening for therapeutic agents. Also disclosed is the new pathway as a means for cells to down-regulate the expression of Staul-binding mRNAs. | 2013-11-28 |
20130317088 | Selective Reduction of the Deleterious Activity of Extended Tri-Nucleotide Repeat Containing Genes - Aspects of the invention include methods of selectively reducing the deleterious activity of mutant extended trinucleotide repeat containing genes in a cell, as well as compositions used in such methods. The deleterious activity (e.g., toxicity and/or dis-functionality of products encoded thereby) of a mutant extended trinucleotide repeat containing gene may be selectively reduced in a variety of different ways, e.g., by selectively decreasing SPT4 mediated transcriptional activity, by enhancing functionality of proteins encoded thereby, etc. Aspects of the invention further include assays for identifying agents that find use in methods of the invention, e.g. as summarized above. Methods and compositions of the invention find use in a variety of different applications, including the prevention or treatment of disease conditions associated with the presence of genes containing mutant extended trinucleotide repeats, such as Huntington's Disease (HD). | 2013-11-28 |
20130317089 | Compositions and Methods Useful for Treatment and Prevention of Incontinence - Compositions and methods effective for increasing bladder control are provided. | 2013-11-28 |
20130317090 | INHIBITION OF CHOROIDAL NEOVASCULARIZATION - Methods of treatment of diseases that include or are characterized by inappropriate or pathological neovascularization are disclosed. These diseases include diseases of the eye, such as diabetic retinopathy, retinopathy of prematurity, and choroidal neovascularization which can occur in age-related macular degeneration (AMD). Disclosed methods include administering agents that cause directly or indirectly upregulation of the ABCA1 transporter protein in macrophages. These agents include, without limitation, LXR agonists. In some embodiments, inhibitors of CETP expression or activity can also be effective. Administration routes can include, without limitation, intraocular, periocular, or systemic administration. | 2013-11-28 |
20130317091 | PROMOTERS, EXPRESSION CASSETTES, VECTORS, KITS, AND METHODS FOR THE TREATMENT OF ACHROMATOPSIA AND OTHER DISEASES - The present invention provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of genetic diseases that affect the cone cells of the retina. | 2013-11-28 |
20130317092 | AGENTS, COMPOSITIONS AND METHODS FOR TREATING PATHOLOGIES IN WHICH REGULATING AN ACHE-ASSOCIATED BIOLOGICAL PATHWAY IS BENEFICIAL - The present invention provides agents which are capable of regulating the function of a micro-RNA component which can be used to regulate an AChE-associated biological pathway. In addition, the present invention provides methods and pharmaceutical compositions for the treatment of various pathologies related to AChE-associated biological pathways such as apoptosis, aberrant cholinergic signaling, abnormal hematopoietic proliferation and/or differentiation, cellular stress, exposure to inflammatory response-inducing agents, and/or exposure to organophosphates or other AChE inhibitors. | 2013-11-28 |
20130317093 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH APO A-1 MILANO - This invention relates to the treatment of Alzheimer's disease, the reduction of the progression of Alzheimer's disease, and the alleviation of symptoms of Alzheimer's disease by administering ApoA-1 Milano based therapies to provide anti-inflammatory, antioxidant, and lipid depleting effects to brain tissue. In particular embodiments, the method comprises administering a composition comprising an rAAV vector encoding ApoA-1 Milano or an active fragment thereof, to a mammal having Alzheimer's disease or a symptom of Alzheimer's disease. | 2013-11-28 |
20130317094 | USE OF ELLAGITANNINS AS INHIBITORS OF BACTERIAL QUORUM SENSING - Described herein are materials and methods for the inhibition of bacterial QS. Methods of treating bacterial infections by administration of one or more ellagitannins in amount effective to inhibit bacterial QS is also provided. | 2013-11-28 |
20130317095 | Use of Artemisine Derivatives and Pharmaceutical Salts Thereof - The invention demonstrates the application of an artemisinin derivative and its pharmaceutical salt. The artemisinin derivatives diarteether amine and its pharmaceutical salt inhibit the proliferation of leukemic cells, block the cell cycle of leukemic cells and induce the apoptosis of leukemic cells. Artemisinin derivatives of the present invention and its pharmaceutical salt can be used for the preparation of anti-leukemia medicines, especially for treatment of acute leukemia and, what's more, for the treatment of acute myeloid leukemia. | 2013-11-28 |
20130317096 | SYNERGISTIC INTERACTION OF AT LEAST ONE VITAMIN E COMPONENT AND TYROSINASE INHIBITORS FOR DERMATOLOGICAL APPLICATIONS - The present invention is directed to a method of treating a dermatological condition or preventing a dermatological condition from occurring or for altering the pigmentation of the skin by administering to a patient a pharmaceutically effective amount of a composition comprising at least one Vitamin E component and at least one additional component different from the Vitamin E component that has anti-tyrosinase activity and/or anti-melanogenesis activity. The present invention is further directed to a pharmaceutical composition comprising at least one Vitamin E component and at least one additional component different from the Vitamin E component that has anti-tyrosinase activity and/or anti-melanogenesis activity. | 2013-11-28 |
20130317097 | STABLE COMPOSITIONS OF DEHYDROASCORBIC ACID - The invention relates to stable liquid compositions containing the oxidized form of vitamin C known as dehydroascorbic acid (DHAA). The compositions comprise DHAA and a pharmacologically acceptable liquid organic polyol solvent. The polyol solvent comprises about 50% or greater of the total weight of the composition. The compositions are useful as dietary supplements, skin-enhancers, concentrates, or research solutions. | 2013-11-28 |
20130317098 | PROTECTIVE HYDROCOLLOID FOR ACTIVE INGREDIENTS - (Modified) sorghum protein is used as novel protective hydrocolloid for active ingredients, especially fat-soluble active ingredients and/or colorants. Included are compositions comprising (modified) sorghum protein and at least one active ingredient and to their manufacture, as well as to the (modified) sorghum protein itself and its manufacture. These compositions are used for the enrichment, fortification and/or coloration of food, beverages, animal feed, personal care or pharmaceutical compositions, and to food, beverages, animal feed, personal care and pharmaceutical compositions containing such a (modified) sorghum protein and such a composition, respectively. | 2013-11-28 |
20130317099 | Picropodophyllin Polymorphs B or C for Use in Cancer Therapy - The invention relates to novel polymorphs of picropodophyllin, methods for preparing said polymorphs and pharmaceutical compositions comprising said polymorphs, as well as the use of said polymorphs in therapy such as cancer therapy. | 2013-11-28 |
20130317100 | PROCESS FOR THE PREPARATION OF 3-AROYL-5-AMINOBENZOFURAN DERIVATIVES - The present invention relates to a process for the preparation of 3-aroyl-5-aminobenzofuran derivatives useful as antiarrhythmic drugs which avoids the use of nitro intermediates. | 2013-11-28 |
20130317101 | SINGLETON INHIBITORS OF SUMOYLATION ENZYMES AND METHODS FOR THEIR USE - According to the embodiments described herein, a SUMOylation inhibitor compound comprising a singleton scaffold is provided. In some embodiments, a method for inhibiting a SUMOylation enzyme in a cell is provided. Such a method may include administering a SUMOylation inhibitor compound to the cell. In some aspects, the SUMOylation enzyme is SUMO E1 or SUMO E2. In some aspects, the method may be used to inhibit a cancer cell in vitro (e.g., grown in culture) or in vivo (e.g., as part of a tumor in a subject). In other embodiments, a method for treating a cancer, degenerative diseases and viral infection is provided. Such a method may include administering an effective amount of a pharmaceutical composition to a subject having the cancer. The pharmaceutical composition may include a singleton SUMOylation inhibitor compound. In some embodiments, the method for treating a cancer may further comprise administering one or more DNA-damaging therapy in combination with administration of the pharmaceutical composition. | 2013-11-28 |
20130317102 | Novel Esters of (Acyloxymethyl)Acrylamide, a Pharmaceutical Composition Containing Them, and Their use as Inhibitors of the Thioredoxin - Thioredoxin Reductase System - The subject of the present invention are novel esters of (acyloxymethyl)acrylamide, a pharmaceutical composition containing them and their use in the production of drugs for the prophylaxis or treatment of oncogenic diseases and diseases connected with increased cell proliferation. | 2013-11-28 |
20130317103 | NRF2 Screening Assays and Related Methods and Compositions - Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death. | 2013-11-28 |
20130317104 | USE OF OLIGOMERS OF LACTIC ACID IN THE TREATMENT OF GYNAECOLOGICAL DISORDERS - The invention relates to the use of one or more oligomers of lactic acid or a lactic acid oligomeric product for the prophylaxis and/or treatment of a disease or condition that benefits from an acidic environment, especially a gynaecological infection including a bacterial infection such as bacterial vaginosis, unspecific colpitis, senile colpitis, cervicitis, and urethritis, a fungal infection, such as candidosis ( | 2013-11-28 |
20130317105 | SILICONE MODIFIED FATTY ACIDS, METHOD OF PREPARATION AND USAGE THEREOF - The present invention relates to silicone modified fatty carboxylic acid compounds. More specifically, the present invention is derived from low molecular weight, i.e., short chain, silicone modified fatty carboxylic acids, their use and method of making same. The present invention provides for a silicone compound partially derived from a natural product, sapucainha oil, for use in cosmetic formulations. | 2013-11-28 |
20130317106 | METHODS FOR MAKING RETINOIDS AND USES THEREOF - Described herein are methods for making retinoids. Also described herein are retinoids and methods of use thereof. | 2013-11-28 |
20130317107 | Platelet-Based Methods to Detect and Monitor Treatment Benefits in Mucosal and Nervous Systems Diseases - The described invention provides methods for treating a disease, disorder or condition comprising an inflammatory component that includes a platelet dysfunction component and methods for monitoring therapeutic efficacy of a therapeutic regimen for managing a disease comprising an inflammatory component that includes platelet dysfunction. | 2013-11-28 |
20130317108 | DERMATOLOGICAL FOAMS OBTAINED FROM A GEL OR SUSPENSION CONTAINING A COMBINATION OF ADAPALENE AND BENZOYL PEROXIDE - Intermediate compositions, and in particular gels and suspensions for foam compositions, are described that include adapalene and benzoyl peroxide in combination. Also described; is the dermatological use of such compositions. | 2013-11-28 |
20130317109 | PROCESS FOR THE PREPARATION OF LACOSAMIDE - There is provided a process for the preparation of Lacosamide (which is a useful medicament) of formula I, which comprises an enantioselective enzymatic acylation. | 2013-11-28 |
20130317110 | COMPOUND, KINESIN SPINDLE PROTEIN INHIBITOR, AND APPLICATION THEREOF - A compound represented by the following General Formula (I): | 2013-11-28 |
20130317111 | DESENSITIZING DRUG PRODUCT - Desensitizing drug products, methods of making desensitizing drug products, and methods of using desensitizing drug products including delivery of desensitizing drug products. In one embodiment, the desensitizing drug products are male genital desensitizers that comprise one or anesthetic agents and one or more melting point depressing agents. | 2013-11-28 |
20130317112 | STORAGE-STABLE FORMULATION OF PARACETAMOL IN AQUEOUS SOLUTION - The present invention relates to a method for the production of a formulation that is stable to oxidation and that is based on paracetamol in an aqueous solvent, comprising the steps of (i) dissolving paracetamol in an aqueous solvent comprising an isotonic agent that is sodium chloride and a buffer agent that is sodium citrate, having a temperature between 65° C. and 95° C. and having pH between 5.0 and 6.0 in a reaction vessel, (ii) replacing the remaining air in the vessel by an inert gas, such as nitrogen, and cooling the solution so formed to a temperature below 38° C., (iii) adding cysteine hydrochloride to the solution without mechanical agitation, and (iv) closing the reaction vessel and mechanically agitating the solution in a nitrogen atmosphere. The further relates to a formulation prepared according to the method. | 2013-11-28 |
20130317113 | REGULATION OF OSTEOPONTIN - The present invention provides methods for the regulation of osteopontin activity in a subject as well as for treating or preventing conditions associated with an increased activity of osteopontin activity in a subject. | 2013-11-28 |
20130317114 | Hydroxylated Tricyclic Compounds - The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the water-soluble oligomer. | 2013-11-28 |
20130317115 | Composition and Method for Treating Neurological Disease - A method of administering amantadine is provided. The method comprises orally administering to a subject a pharmaceutical composition comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of the amantadine. A dose of the composition provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is less than 40% of the change in amantadine plasma concentration provided by a dose of the same quantity of an immediate release form of amantadine. The change in plasma concentration over time (dC/dT) is measured in a single dose human pharmacokinetic study in a defined time period of 0 to 4 hours after administration. The amantadine, or pharmaceutically acceptable salt thereof, is administered once daily at a dose of 300 to 500 mg per day. | 2013-11-28 |
20130317116 | EXTERNAL SKIN PREPARATION - This invention provides an external skin preparation with high safety aimed at wrinkle improvement and wrinkle prevention. Specifically, the invention relates to an external skin preparation comprising, as an active ingredient, a carotenoid. | 2013-11-28 |
20130317117 | SELF MICRO-EMULSIFYING DRUG DELIVERY SYSTEM WITH INCREASED BIOAVAILABILITY - The invention provides a formulation comprising (a) a drug that is poorly water-soluble, (b) at least one surfactant, and (c) at least one polar lipid, wherein the formulation is substantially free of a polar solvent, as well as methods of preparing the formulation and methods of increasing the bioavailability of a drug using the formulation. | 2013-11-28 |
20130317118 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM - The present invention relates to compounds of formula I and II, which are functionalized amino acids, and polymers formed from the same. | 2013-11-28 |
20130317119 | Poly-Alpha-Olefin -Containing Cosmetic Composition - The invention is directed to a cosmetic composition which contains at least one poly-α-olefin produced by subjecting at least one primary alcohol to dehydrating polymerization at a temperature of 60° C. to 340° C. in the presence of acidic alumino layer silicates. The primary alcohol is an alcohol from the group of unsaturated monofunctional alcohols, branched monofunctional alcohols and difunctional alcohols. The poly-α-olefin is a high-spreading oil component which imparts an almost instantaneous and relatively long-lasting feeling of smoothness to the skin and has good dermatological compatibility. | 2013-11-28 |
20130317120 | FUNCTIONALIZED NON-PHENOLIC AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM - The present invention relates to compound of formula I, which are functionalized, non-phenolic amino acids, and polymers formed from the same. | 2013-11-28 |
20130317121 | METHOD FOR THE PREPARATION OF PLYMERS WITH VARIED ARCHTECTURE AND AMIDE INITIATION - The invention relates to a method for preparing linear polymers having an amide end or having a star architecture comprising an amide core, by means of a ring opening using lactide and glycolide monomers or a lactide monomer ring in the presence of a catalyst, wherein the method includes the steps of: (i) reacting the excess monomer(s) with an initiator in a solvent, said initiator being selected from among an amine and an amino alcohol, given that the initiator has at least one primary or secondary amine function; (ii) adding a catalyst, said catalyst being a non-nucleophilic base and including at least one neutral sp2 nitrogen atom; and (iii) neutralizing the reaction mixture. Said novel method is particularly advantageous in that it can be easily monitored and enables better modulation of the polymers, and thus of the properties thereof, than the methods of the prior art. The invention also relates to novel polymers that are obtainable by means of said method. | 2013-11-28 |
20130317122 | TRANSDERMAL DELIVERY SYSTEM - A transdermal delivery system comprising a composition comprising a physiologically active agent and a penetration enhancer wherein the penetration enhancer comprises a combination of (i) an ester of salicylic acid, preferably selected from the C | 2013-11-28 |
20130317123 | LARGE DELETIONS IN HUMAN PMS2 GENE AND USE THEREOF - Large deletions have been identified in the PMS2 gene in patients. The large deletions predispose the patients to Lynch syndrome associated cancers. | 2013-11-28 |
20130317124 | NOVEL SINGLE NUCLEOTIDE POLYMORPHISMS AND COMBINATIONS OF NOVEL AND KNOWN POLYMORPHISMS FOR DETERMINING THE ALLELE-SPECIFIC EXPRESSION OF THE IGF2 GENE - Single nucleotide polymorphisms and uses for determining the imprinting status of the Insulin Growth Factor-2 gene in a clinical specimen are described. | 2013-11-28 |
20130317125 | NOVEL SINGLE NUCLEOTIDE POLYMORPHISMS AND COMBINATIONS OF NOVEL AND KNOWN POLYMORPHISMS FOR DETERMINING THE ALLELE-SPECIFIC EXPRESSION OF THE IGF2 GENE - Single nucleotide polymorphisms and uses for determining the imprinting status of the Insulin Growth Factor-2 gene in a clinical specimen are described. | 2013-11-28 |
20130317126 | PROCESS FOR GENERATING A SYNTHETIC NATURAL GAS - A process is described for reducing the thiophene content in a synthesis gas mixture, comprising comprises the steps of (i) passing a synthesis gas mixture comprising hydrogen and carbon oxides and containing thiophene over a copper-containing sorbent disposed in a sorbent vessel at an inlet temperature in the range 200-280 oC, (ii) withdrawing a thiophene depleted synthesis gas containing methanol from the sorbent vessel, and (iii) adjusting the temperature of the methanol-containing thiophene-depleted synthesis gas mixture. The resulting gas mixture may be used for production of chemicals, e.g. methanol production or for the Fischer-Tropsch synthesis of liquid hydrocarbons, for hydrogen production by using water gas shift, or for the production of synthetic natural gas. | 2013-11-28 |
20130317127 | Nickel-M-Alumina Xerogel Catalyst, Method for Preparing the Same, and Method for Preparing Methane Using the Catalyst - A nickel-M-alumina hybrid xerogel catalyst for preparing methane, wherein the metal M is at least one element selected from the group consisting of Fe, Co, Ni, Ce, La, Mo, Cs, Y, and Mg, a method for preparing the catalyst and a method for preparing methane using the catalyst are provided. The catalyst has strong resistance against a high-temperature sintering reaction and deposition of carbon species, and can effectively improve a conversion ratio of carbon monoxide and selectivity to methane. | 2013-11-28 |
20130317128 | Process for Making a Monomer Solution for Making Cation Exchange Membranes - A method of making a monomer solution of styrene sulfonic acid or the pyridine salt of styrene sulfonic acid or mixtures of both in an organic solvent, said solution being suitable for producing cation exchange membranes. The method comprises the steps of dissolving a metal salt of styrene sulfonate in said organic solvent and pyridinium styrene sulfonate. The mixture solution is reacted under conditions that generate a salt byproduct precipitate and the reactant product solution is collected. Embodiments of the present invention provide for cation exchange membranes and processes for their manufacture. Membranes made by the processes described herein combine low resistance and high permselectivity which make them highly effective for membrane components in desalination of water by electrodialysis (ED), as a power generating sources in reverse electrodialysis and as separators in fuels cells. | 2013-11-28 |
20130317129 | TEMPERATURE RESPONSIVE ADSORBENT HAVING A STRONG CATION EXCHANGE GROUP AND METHOD FOR PRODUCING THE SAME - Provided is a temperature responsive adsorbent prepared by immobilizing a copolymer containing at least N-isopropylacrylamide to a base material surface. The copolymer has at least a strong cation exchange group. In addition, the copolymer contains the strong cation exchange group in an amount of 0.01 to 5 mol % relative to N-isopropylacrylamide in terms of monomer. | 2013-11-28 |
20130317130 | 3D Microfluidic Devices Based on Open-Through Thermoplastic Elastomer Membranes - The invention provides a new process for patterning TPE membranes for use in the design and fabrication of 3D microfluidic devices. The process involves patterning a TPE material without permitting the highest features of the mold to come into contact with the counter-plate, whereby adhesion between the TPE and the mold or counter-plate during demolding results directly in removal of the excess layer from the TPE membrane to produce well formed micrometric-sized open-through holes in the TPE membrane. The process permits rapid, reliable and efficient patterning of densely packed and arbitrarily placed micrometric open-through holes and channels of high aspect-ratio and any shape or wall profile in thin TPE membranes. | 2013-11-28 |
20130317131 | POLYMERS AND NANOGEL MATERIALS AND METHODS FOR MAKING AND USING THE SAME - Provided are compositions comprising a block copolymer of the following formula: [A]-B-[Q], wherein [A] is a polymer that has an affinity for a substrate; B is a linking group comprising an optionally-substituted, polyvalent linking group having a molecular weight of no more than 1000 g/mole; and [Q] comprises a semi-crosslinked, ungelled polymer derived from copolymerization of an ethylenically unsaturated monomer with a poly-functional ethylenically unsaturated monomer. Such block copolymers are cross-linked via the [Q] segment, but not macroscopically gelled. The [Q] segment is hydrophilic and has a degree of polymerization in the range of about 10 to about 10,000. The [A] segment is located on at least one terminal end of said block copolymer, comprises between about 1 and about 200 repeating units. The block copolymer is associated, via the linear substrate associative segment with a surface comprising at least one hydrophobic site, such as a silicone hydrogel. The polymers may be incorporated into a formulation from which the silicone hydrogel is made or may be contacted with the silicone hydrogel post-formation. | 2013-11-28 |
20130317132 | CONTACT LENSES COMPRISING WATER SOLUBLE N-2 HYDROXYALKYL) (METH)ACRYLAMIDE POLYMERS OR COPOLYMERS - The present invention relates to biomedical devices, and particularly contact lenses comprising a polymer having entangled therein at least one polymer comprising repeating units from N-(2-hydroxyalkyl)(meth)acrylamide. | 2013-11-28 |
20130317133 | POLYMERS AND NANOGEL MATERIALS AND METHODS FOR MAKING AND USING THE SAME - Provided are articles such as medical devices which comprise at least one water soluble, crosslinked copolymer. The primary polymer chains of the copolymer are hydrophilic and independently have a degree of polymerization in the range of about 10 to about 10,000. The water soluble, crosslinked copolymers of the present invention are free from terminal substrate associating segments. The copolymers may be incorporated into a formulation from which the article is made or may be contacted with the article post-formation. | 2013-11-28 |
20130317134 | TISSUE ADHESIVE BASED ON TRIFUNCTIONAL ASPARTATES - The present invention relates to a compound of formula (I) wherein R | 2013-11-28 |
20130317135 | WATER SHUT-OFF SYSTEM FOR PRODUCTION AND/OR INJECTION WELLS - Water Shut-off (WSO) system comprising organic products with relatively low viscosity, which are pumped to into a well in liquid state, and after a certain period of time, reach the desired consistence that may vary from a rigid gel, to produce a complete water flow blockage, up to deformable gels, which produce only a partial blockage effect, reducing significantly the water passage and still allowing the oil passage. | 2013-11-28 |
20130317136 | OUTDOOR URETHANE ADHESIVE - Disclosed is an outdoor urethane adhesive comprising (A) a urethane resin obtainable by reacting an isocyanate compound (a1) with a polyol having an ester bond (a2), and (B) a hydroxyphenyltriazine based compound, wherein the isocyanate compound (a1) comprises at least one selected from an aliphatic isocyanate and an alicyclic isocyanate. The outdoor urethane adhesive has high peel strength and is excellent in weatherability. More preferably, the outdoor urethane adhesive further comprises a Mane compound. | 2013-11-28 |
20130317137 | ELASTOMERIC COMPOSITION EXHIBITING GOOD DISPERSION OF THE FILLER IN THE ELASTOMERIC MATRIX - The invention relates to a rubber composition based on at least one diene elastomer, a reinforcing filler comprising at least carbon black and an inorganic filler with an inorganic filler content of less than or equal to 50 parts by weight per hundred parts of elastomer, characterized in that the composition is obtained from a first masterbatch comprising at least one first diene elastomer and carbon black, and having a dispersion of the carbon black in the elastomeric matrix that has a Z value of greater than or equal to 90, added to which is the inorganic filler and at least one second elastomer, identical to or different from the first elastomer, and also to the process for preparing such a composition. | 2013-11-28 |
20130317138 | FLAME RETARDANT RESIN COMPOSITION AND MOLDED PRODUCT - A flame retardant resin composition including: a thermoplastic resin; and a flame retardant, wherein the flame retardant includes a phosphorylated lignin derivative, and wherein the phosphorylated lignin derivative is produced by adding phosphoric acid to a lignin derivative obtained by subjecting a naturally occurring lignin to a predetermined treatment. | 2013-11-28 |
20130317139 | LOW GLOSS IONOMER-BASED CAPSTOCK - A low gloss capstock compound is disclosed. The combination of gloss inhibiting agents, metal-based ionomer thermoplastic resins, and acid scavenger added to conventional polyethylene polymer resin achieves a gloss angle at 85° of below 10 GU. Optionally, the compound can also include weathering agents to improve outdoor durability. The compound can be fully formulated or a masterbatch for let-down into polymer to form the fully formulated compound. | 2013-11-28 |
20130317140 | POLYMER COMPOSITION CONTAINING A POLYMER, WHICH POLYMER CONTAINS MONOMER UNITS OF A DIMERISED FATTY ACID - A polymer composition containing a polymer, which polymer contains a residue of a dimerised fatty acid and/or a derivative thereof, which polymer composition contains an epoxidized plasticizer. | 2013-11-28 |
20130317141 | FLAME RETARDANT POLYCARBONATE COMPOSITIONS, METHODS OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME - Disclosed herein is a flame retardant polycarbonate composition comprising 10 to 90 weight percent of a polycarbonate composition, a fibrous reinforcing and a flame retardant composition that comprises a phosphazene compound and a mineral filler synergist. In an embodiment, the polycarbonate composition comprises a first copolyestercarbonate copolymer and a second copolyestercarbonate copolymer, where the first copolyestercarbonate copolymer has a lower molecular weight than the second copolyestercarbonate copolymer. In another embodiment, the polycarbonate composition comprises a linear polycarbonate, a branched polycarbonate, or a combination of a linear and a branched polycarbonate. Disclosed herein too is a method of manufacturing the composition and articles that can be manufactured from the composition. | 2013-11-28 |
20130317142 | FLAME RETARDANT THERMOPLASTIC COMPOSITIONS, METHODS OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME - Disclosed herein is a flame retardant composition comprising 10 to 75 weight percent of a polycarbonate; 10 to 30 weight percent of a polyester; 10 to 35 weight percent of a polysiloxane-polycarbonate copolymer; and a phosphazene flame retardant, where all weight percents are based on the total weight of the flame retardant composition. Disclosed herein too is a method of manufacturing a flame retardant composition comprising blending 30 to 50 weight percent of a polycarbonate; 10 to 30 weight percent of a polyester; 10 to 35 weight percent of a polysiloxane-polycarbonate copolymer; and a phosphazene flame retardant, where all weight percents are based on the total weight of the flame retardant composition. | 2013-11-28 |
20130317143 | FLAME RETARDANT POLYCARBONATE COMPOSITIONS, METHODS OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME - Disclosed herein is a flame retardant composition comprising 20 to 80 weight percent of a polycarbonate composition; where the polycarbonate composition comprises a polysiloxane-carbonate copolymer; an impact modifier in an amount of 0.5 to 25 weight percent; and 1 to 20 weight percent of a phosphazene compound; where all weight percents are based on the total weight of the flame retardant composition. Disclosed herein too is a method comprising blending 20 to 80 weight percent of a polycarbonate composition; where the polycarbonate composition comprises a polysiloxane-carbonate copolymer; an impact modifier in an amount of 0.5 to 25 weight percent; and 1 to 20 weight percent of a phosphazene compound to produce a flame retardant composition; where all weight percents are based on the total weight of the flame retardant composition; and extruding and molding the flame retardant composition. | 2013-11-28 |
20130317144 | FLAME RETARDANT POLYCARBONATE COMPOSITIONS, METHODS OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME - Disclosed herein is a flame retardant composition comprising 20 to 80 weight percent of a polycarbonate; 1 to 20 weight percent of a laser activatable additive; the laser activatable additive being operative to plate the flame retardant composition upon being activated by a laser; and 1 to 20 weight percent of a phosphazene compound; where all weight percents are based on the total weight of the flame retardant composition. Disclosed herein too is a method comprising blending 20 to 80 weight percent of a polycarbonate; 1 to 20 weight percent of a laser activatable additive; the laser activatable additive being operative to plate the flame retardant composition upon being activated by a laser; and 1 to 20 weight percent of a phosphazene compound to produce a flame retardant composition; where all weight percents are based on the total weight of the flame retardant composition; and extruding the flame retardant composition. | 2013-11-28 |
20130317145 | FLAME RETARDANT POLYCARBONATE COMPOSITIONS, METHODS OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME - Disclosed herein is a flame retardant composition comprising a polycarbonate composition, glass fibers, and a flame retardant that comprises a phenoxyphosphazene compound. Disclosed herein too are methods for manufacturing a flame retardant composition that comprises blending a polycarbonate composition, glass fibers and a flame retardant that comprises a phenoxyphosphazene compound. | 2013-11-28 |
20130317146 | FLAME RETARDANT POLYCARBONATE COMPOSITIONS, METHODS OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME - Disclosed herein is a flame retardant composition comprising 10 to 90 weight percent of a linear polycarbonate; a branched polycarbonate; 10 to 70 weight percent of a polysiloxane-polycarbonate copolymer; and 1 to 20 weight percent of a phosphazene compound; were all weight percents are based on the total weight of the composition. Disclosed herein too is a method comprising blending 10 to 90 weight percent of a linear polycarbonate; a branched polycarbonate; 10 to 70 weight percent of a polysiloxane-polycarbonate copolymer; and 1 to 20 weight percent of a phosphazene compound; to form a flame retardant composition; were all weight percents are based on the total weight of the composition. | 2013-11-28 |
20130317147 | FLAME RETARDANT POLYCARBONATE COMPOSITIONS, METHODS OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME - Disclosed herein is a flame retardant composition comprising 10 to 90 weight percent of a linear polycarbonate; 5 to 50 weight percent of a polysiloxane-polycarbonate copolymer; where the polysiloxane-polycarbonate copolymer comprises 10 weight percent or more of polysiloxane and where the molecular weight of the polysiloxane is 30,000 grams per mole or greater; and 1 to 20 weight percent of a phosphazene compound; where all weight percents are based on the total weight of the composition. | 2013-11-28 |
20130317148 | FLAME RETARDANT POLYCARBONATE COMPOSITIONS, METHODS OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME - Disclosed herein is a flame retardant composition comprising a polycarbonate; 5 to 10 weight percent of a polysiloxane-polycarbonate copolymer; where the polysiloxane-polycarbonate copolymer comprises an amount of greater than 10 weigh percent of the polysiloxane and where the molecular weight of the polysiloxane-polycarbonate copolymer is greater than or equal to 25,000 grams per mole; 5 to 20 weight percent of a branched polycarbonate; 5 to 60 weight percent of a reinforcing filler; and 1 to 15 weight percent of a flame retarding compound. Disclosed herein too is a method comprising blending a polycarbonate; 5 to 10 weight percent of a polysiloxane-polycarbonate copolymer; 5 to 20 weight percent of a branched polycarbonate; 5 to 60 weight percent of a reinforcing filler; where the reinforcing filler is a glass fiber, a carbon fiber, a metal fiber, or a combination comprising at least one of the foregoing reinforcing fillers; and 1 to 15 weight percent of a flame retarding compound; and extruding the flame retardant composition. | 2013-11-28 |
20130317149 | FLAME RETARDANT COMPOSITIONS, ARTICLES COMPRISING THE SAME AND METHODS OF MANUFACTURE THEREOF - Disclosed herein is a flame retardant composition comprising a polycarbonate; a polylactide; and a flame retardant; where the flame retardant is a phenoxyphosphazene, a di- or polyfunctional aromatic phosphorus-containing compound, or a combination comprising at least one of the foregoing flame retardants. Disclosed herein is a method comprising blending a polycarbonate, a polylactide and a flame retardant to form a flame retardant composition; where the flame retardant is a phenoxyphosphazene, a di- or polyfunctional aromatic phosphorus-containing compound, or a combination comprising at least one of the foregoing flame retardants. | 2013-11-28 |
20130317150 | FLAME-RESISTANT POLYESTER-POLYCARBONATE COMPOSITIONS, METHODS OF MANUFACTURE, AND ARTICLES THEREOF - A composition comprising a polyester, polycarbonate, organopolysiloxane-polycarbonate block copolymer, organophosphorus flame retardant, fluorinated polyolefin, and one or more additives. In one embodiment, the composition has an improved balance of properties, including one or more of a melt volume rate, Vicat softening temperature, notched Izod impact strength and a UL 94 flammability rating. | 2013-11-28 |
20130317151 | RUBBER COMPOSITION AND TIRE PRODUCED BY USING THE SAME - In order to provide a rubber composition which is improved in dispersibility of silica in rubber compositions and can be improved as well in heat build-up and processability without causing increasing a viscosity of unvulcanized rubber and retarding a vulcanization rate, and a tire prepared by using the same, the rubber composition is endowed with a constitution in which at least one rubber component selected from natural rubber and/or diene base synthetic rubbers is compounded with a white filler and at least one of monoalkanolamides represented by the following Formula (I): | 2013-11-28 |
20130317152 | POLYMER COMPOSITION CONTAINING DINT AS A SOFTENER - The invention relates to a composition comprising at least one polymer selected from the group consisting of polyvinyl chloride, polyvinylidene chloride, polyvinyl butyrate, polyalkyl (meth)acrylate and copolymers thereof, and diisononyl terephthalate (DINT) as plasticizer, where the average degree of branching of the isononyl groups of the ester is in the range from 1.15 to 2.5, and at least one additional plasticizer which reduces processing temperature. | 2013-11-28 |
20130317153 | DIISONONYL TEREPHTHALATE (DINT) AS SOFTENER FOR THERMOPLASTIC APPLICATIONS - The present invention relates to the use of diisononyl terephthalate (DINT) as plasticizer for enhancing the low-temperature flexibilization and/or for enhancing the permanence in polymer compositions for thermoplastic applications. | 2013-11-28 |
20130317154 | Plasticized compositions containing estolide compounds - Provided herein are compounds of the formula: | 2013-11-28 |
20130317155 | FLEXIBLE BENZOXAZINE RESIN - One or more embodiments contained herein disclose an adhesive for printed circuit board (PCB) applications. The improved adhesive may comprise a benzoxazine resin and a polyester plasticizer. | 2013-11-28 |
20130317156 | Functional norbornanyl ester derivatives, polymers and process for preparing same - This invention relates to the new functional norbornanyl ester derivative and/or polymer compositions which are easily obtainable by reacting the Diels-Alder adduct of appropriate dienes and dienophiles with carboxylic acids. In particular, this invention relates to a new process for making cyclic chemical raw materials suitable for production coating, ink, adhesive, plasticizer, thermoplastic or thermosetting plastic and functional polymers. | 2013-11-28 |
20130317157 | VINYL CHLORIDE RESIN COMPOSITION - Disclosed is a vinyl chloride resin composition that is excellent in thermal stability, coloring resistance and processability, free from heavy metal stabilizers such as lead, tin and barium, and thus is suitable for use in building materials, and specifically provides a vinyl chloride resin composition containing (a) an organic acid calcium salt and/or an organic acid zinc salt, (b) calcium acetylacetonate and/or zinc acetylacetonate, (c) a hydrotalcite compound and (d) a polyol mixture in specific contents with respect to a vinyl chloride resin, wherein a polyol mixture having a specific composition is used as the polyol mixture that is the component (d). | 2013-11-28 |